Original articlesImproving glycemic control in the cardiothoracic intensive care unit: Clinical experience in two hospital settings☆
Section snippets
Methods
The Yale New Haven Hospital (YNHH) CTICU is an 18-bed unit located in a 944-bed tertiary care referral center in New Haven, CT. Sixty-three percent of YNHH CTICU patients are admitted for coronary artery bypass grafting (CABG), 18% for cardiac valve surgery, and 12% for a combined CABG-valve procedure. Thirty-one percent of patients admitted to the YNHH CTICU remain for less than 24 hours; 44% stay longer than 48 hours.
The Hospital of Saint Raphael’s (HSR) CTICU is a 16-bed unit located in a
Results
At the time of data analysis, the IIP had been used 137 times in 118 patients (YNHH, 81 infusions in 71 patients; HSR, 56 infusions in 47 patients). Baseline characteristics of the 118 IIP patients are shown in Table 1, including their primary reason for CTICU admission. Notably, YNHH and HSR patients were similar in most respects. YNHH patients had a somewhat greater severity of illness (APACHE II score), which was expected, given that YNHH is a tertiary care referral center. For all 118
Discussion
The authors’ intensive IIP was successful in improving BG levels in 2 CTICUs, with rare and clinically insignificant hypoglycemia. Importantly, the authors’ protocol was equally effective in a tertiary referral center and in a community teaching hospital. Additionally, because the IIP has previously been proven effective in medical ICU patients,5 the authors suspect that it could be applied in a variety of clinical settings. The generalizability of the IIP is one if its important strengths.
Acknowledgements
IIP implementation, data collection, data analysis, and manuscript review were assisted by Robert Sherwin, MD, Mark Siegel, MD, James Dziura, PhD, James McCabe, BS, Daniel Prince, BS, Surani Fernando, MD, Amy Nuernberg, MD, John Aversa Jr, DO, Odile Anderson, MSN., APRN, Jennifer Doward, MSN, RN, and Joshua Halickman. The authors are also indebted to the following cardiothoracic surgeons involved in this project: Peter Barrett, MD, Charles Beckman, MD, Michael Dewar, MD, John Elefteriades, MD,
References (31)
- et al.
Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting
J Thorac Cardiovasc Surg
(2003) - et al.
The 1996 coronary artery bypass risk modelThe Society of Thoracic Surgeons adult cardiac national database
Ann Thorac Surg
(1999) - et al.
Trauma metabolism of the heartUptake of substrates and effects of insulin early after cardiac operations
J Thorac Cardiovasc Surg
(1990) - et al.
Glucose-insulin-potassium solutions enhance recovery following urgent CABG surgery
J Thorac Cardiovasc Surg
(1997) - et al.
Glucose-insulin-potassium solutions improve outcomes in diabetics who have coronary artery operations
Ann Thorac Surg
(2000) - et al.
Glucose-insulin-potassium in acute myocardial infarction
Lancet
(1999) - et al.
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study)Effects on mortality at 1 year
J Am Coll Cardiol
(1995) - et al.
Description and evaluation of a glycemic management protocol for patients with diabetes undergoing heart surgery
Endocr Pract
(2002) - et al.
Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures
Ann Thorac Surg
(1999) - et al.
Intensive insulin therapy in critically ill patients
N Engl J Med
(2001)
Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit
Diabetes Care
APACHE IIA severity of disease classification system
Crit Care Med
Risk factors for poor glycemic control in a medical intensive care unit (MICU)
Diabetes
Alterations in carbohydrate metabolism during stressA review of the literature
Am J Med
Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes
Diabetes Care
Cited by (0)
- ☆
Supported by fellowship training grants from the Juvenile Diabetes Research Foundation (File #3-2003-95) and from Eli Lilly and Company (Indianapolis, IN), and NIH General Clinical Research Center Grant RR125.